BiomX presents positive data from Phase 1b/2a clinical trials for BX004 at the European Respiratory Society (ERS) Congress 2024 Page 1

GAITHERSBURG, Maryland, Sept. 3, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company developing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces that the Company has received data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa Lung infections. The results will be presented as a poster at the European Respiratory Society (ERS) Congress, 7-11 September 2024, in Vienna, Austria. The poster will be presented on Monday, 9 September 2024, from 8:00 to 9:30 am local time, at poster session 234: “Navigating the journey of adult cystic fibrosis: past and future perspectives” (room PS-21; panel number 2, poster ID 2341).

The poster entitled “Novel nebulized phage cocktail in CF patients with chronic P. aeruginosa pulmonary infections: a Ph1b/2a randomized, double-blind, placebo-controlled trial,” reports that the company’s phage cocktail BX004-A demonstrated favorable safety and remarkable microbiological and clinical efficacy in cystic fibrosis patients with chronic P. aeruginosa
Lung infections, including in patients receiving standard treatment with elexacaftor/tezacaftor/ivacaftor (ETI). The poster will be available on the company's website following the poster session.

“These data, summarizing our previously announced Phase 1b/2a study, continue to be encouraging and support our novel approach to treating cystic fibrosis. The European Respiratory Society is an important opportunity to share these results with the European scientific community and we are grateful to be able to share these positive data,” commented Jonathan Solomon, CEO of BiomX.

The summary of the data shows the first results of the two-part study, which are explained in more detail in the poster. In the first part of the study, the subjects who received the cocktail BX004-A showed a greater reduction in P. aeruginosa (PsA) colony forming units (CFU)/g sputum at day 15 from baseline compared to placebo. Importantly, in the second part of the study, 14% of subjects receiving BX004-A had a negative PsA sputum culture at day 10 (end of treatment) compared to placebo (0%)*. In addition, lung function, as measured by forced expiratory volume in 1 second (FEV1), improved in subjects receiving the cocktail (+5.66%) compared to placebo (-3.23%), in the subgroup with continuously inhaled antibiotics (same antibiotic without cycling or rotation regimen), with ETI and with lower lung function (FEV1

Discuss the values ​​contained